Stay updated on Nivolumab and Relatlimab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe study record adds posted results and a new Phase II description with expanded endpoints and timing for efficacy measurements (e.g., ORR, PFS, PD-1/LAG-3 expression, and tumor assessments).SummaryDifference9%

- Check18 days agoChange DetectedThe related topics section now lists Melanoma and MedlinePlus Genetics. This is a navigational/content enhancement that helps users connect the study with its disease context and genetics resources without changing any trial data.SummaryDifference0.2%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe revision tag on the page updated from v3.6.4 to v3.6.5. This reflects a new version of the page in the revision history.SummaryDifference0.1%

- Check46 days agoChange DetectedA new Revision: v3.6.4 tag has been added. The previous Revision: v3.6.3 tag, along with certain related topics text (Melanoma, MedlinePlus Genetics), was removed.SummaryDifference0.2%

- Check68 days agoChange DetectedMetadata and related topics were updated, and the revision tag was changed from v3.6.2 to v3.6.3. These changes adjust navigation and context without altering the study details.SummaryDifference0.2%

- Check75 days agoChange DetectedThe page’s revision label was updated from v3.6.0 to v3.6.2 to reflect a new build. This update records the updated software version without changing the page’s content or functionality.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and Relatlimab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.